Opendata, web and dolomites


Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles

Total Cost €


EC-Contrib. €






 SMARTRIOX project word cloud

Explore the words cloud of the SMARTRIOX project. It provides you a very rough idea of what is the project "SMARTRIOX" about.

17    primarily    releases    positioning    progesterone    chemotherapy    immune    adjuvant    grow    billion    exclusively    accounts    threshold    burden    tumour    lower    treatment    roi    mg2    cells    tnbc    turn    innovative    orphan    trioxnano    company    lacks    market    ttriple    suffering    estrogen    interval    although    ease    herceptin    causes    anticancer    economic    neoadjuvant    substantial    world    primary    anthracycline    national    machine    concentrations    free    shows    shortened    txn770    course    molecular    bcs    extremely    atp    10    aggressive    toxicities    mainstay    dose    prognosis    oncologists    render    metastatic    digestive    dnazyme    helpful    diagnosis    doxorubicin    cancer    prevents    services    negative    itself    disease    achieves    bc    nonetheless    nano    epithelial    bionanoparticle    cap    triox    patients    inside    women    receptors    15    limit    yearly    therapies    resistant    effectiveness    547m    date    25    2021    cardiac    maximal    setting    recognizes    levels    breast    diagnosed    responding    times    programmed    potent    200    health    invested    endocrine    profit    poor    settings   

Project "SMARTRIOX" data sheet

The following table provides information about the project.


Organization address
address: ROKACH SHIMON 4
postcode: 9518705
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 2˙847˙667 €
 EC max contribution 1˙993˙367 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRIOX NANO LTD IL (JERUSALEM) coordinator 1˙993˙367.00


 Project objective

Although there are tTriple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2 and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC.


List of deliverables.
Project Web page Websites, patent fillings, videos etc. 2020-01-14 14:23:12

Take a look to the deliverables list in detail:  detailed list of SMARTRIOX deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMARTRIOX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMARTRIOX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)


Read More  


Eco-friendly smart doors for non-residential building fire protection

Read More